Add news
March 2010
April 2010
May 2010June 2010July 2010
August 2010
September 2010October 2010
November 2010
December 2010
January 2011
February 2011March 2011April 2011May 2011June 2011July 2011August 2011September 2011October 2011November 2011December 2011January 2012February 2012March 2012April 2012May 2012June 2012July 2012August 2012September 2012October 2012November 2012December 2012January 2013February 2013March 2013April 2013May 2013June 2013July 2013August 2013September 2013October 2013November 2013December 2013January 2014February 2014March 2014April 2014May 2014June 2014July 2014August 2014September 2014October 2014November 2014December 2014January 2015February 2015March 2015April 2015May 2015June 2015July 2015August 2015September 2015October 2015November 2015December 2015January 2016February 2016March 2016April 2016May 2016June 2016July 2016August 2016September 2016October 2016November 2016December 2016January 2017February 2017March 2017April 2017May 2017June 2017July 2017August 2017September 2017October 2017November 2017December 2017January 2018February 2018March 2018April 2018May 2018June 2018July 2018August 2018September 2018October 2018November 2018December 2018January 2019February 2019March 2019April 2019May 2019June 2019July 2019August 2019September 2019October 2019November 2019December 2019January 2020February 2020March 2020April 2020May 2020June 2020July 2020August 2020September 2020October 2020
News Every Day |

Pfizer CEO: ‘Disappointed’ in presidential debate, vows no political pressure on Covid shot

The CEO of Pfizer — one of the frontrunners in the coronavirus vaccine race — said in a staff memo Thursday that the company wouldn’t cave to political pressure to rush its vaccine to market, while at the same time decrying "those who argue for delay."

“Tuesday night I joined the millions of Americans who tuned in to the Presidential debate. Once more, I was disappointed that the prevention for a deadly disease was discussed in political terms rather than scientific facts,” Albert Bourla said in an internal memo obtained by POLITICO.

President Donald Trump said Tuesday during the first 2020 presidential debate that the country is “weeks away from a vaccine” contradicting federal health officials who project a shot will be available at the end of the year or early 2021. Democratic candidate Joe Biden countered that on “the whole notion of a vaccine — I don’t trust him at all, you don’t either.”

Bourla has repeatedly said that Pfizer could apply for emergency authorization from the FDA sometime in October, the most ambitious target laid out by any of the vaccine developers whose shots are now in late-stage U.S trials.

His memo to staff Thursday sticks to that goal while also asserting Pfizer's independence in the face of strong pressure from the White House to deliver a shot before Election Day.

"Now, we are approaching our goal and despite not having any political considerations with our pre-announced date, we find ourselves in the crucible of the U.S. Presidential election," Bourla wrote, later adding "we would never succumb to political pressure."

Trump last week said he might block FDA's proposal to strengthen its standards for allowing emergency use of Covid-19 vaccines — standards that would almost certainly rule out having a vaccine ready for use by early November. The president also accused FDA of acting based on political considerations, rather than science, without offering any evidence to support the claim.

The plan for Pfizer's ongoing Phase III vaccine trial allows the company to take its first look at data when just 32 participants, out of a planned 44,000, have reported Covid-19 infections.

The CEO of another coronavirus vaccine frontrunner, Moderna, said this week that the company would not file for authorization before late November; AstraZeneca’s U.S. trials are still stalled pending FDA investigation of a serious side effect. Other shots are still in early trials or just entered the final, monthslong phase recently.

Pfizer and its partner BioNTech contracted with the U.S. government in July to provider 100 million doses of their shot to Health and Human Services and the Pentagon for $1.95 billion and an option to buy 500 million more doses.

Read also

Miss Manners: She’s planning a wedding but she doesn’t have the ring

Trump, Biden to have microphones muted for part of final US presidential debate

Foreign investors losing trust in Malta's political stability, survey shows

News, articles, comments, with a minute-by-minute update, now on — latest news 24/7. You can add your news instantly now — here